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There are conﬂicting ﬁndings in literature about the structural changes of the primary varicose veins. NO (a potent vasodilatator)
is synthesized by nitric oxide synthase (NOS). From 3 known NOS isoforms the two are constitutional: eNOS (endothelial NOS)
and nNOS (neuronal NOS). 10 varicose and 10 control vein samples were processed by standard light microscopy and immuno-
histochemica techniques using rabbit polyclonal antibodies against eNOS and nNOS. Antibodies expression was evaluated
semiquantitatively and proved morphometrically by 2D-image analysis. total area of NOS isoforms expressions was determined
by color analysis and color digital subtraction. The results showed discontinuous and signiﬁcantly lower expression of both NOS
isoformsthe in the tunica media of varicose veins compared with the control group. For the statistical analysis the unpaired t-test
was used. Our results suppose lower NO levels in varicose vein wall, deducing that varicose dilatation is due to other mechanism,
and they contradict the results of previously published similar works.
1.Introduction
Varicose veins are dilated, tortuous, and elongated veins
aﬀecting especially the superﬁcial veins of the lower limbs.
Beside the post-hrombotic syndrome and crural ulcer, they
represent only one of the symptoms of the chronic venous
disease—a relatively frequent vascular disease aﬀecting the
lower limbs veins of the persons in productive age [1].
The incidence of the chronic venous disease accounts for
about 40–60% in females and 15–30% in males in the
developedcountries of Europe and USA [2]. According to its
etiology we distinguish its primary form (cause unknown)
and secondary form (occurring usually as a consequence
of the survived deep lower limb phlebothrombosis). As the
exact cause of the primary form has not yet been revealed,
the therapy of this form still resides mainly in reducing
the symptoms. The cause of the primary form of varicosis
remains tobethesubject ofinterest ofseveralinvestigatorsin
the world. There is ethiopathogenetic association between
(a) venous wall weakness associated with alterations in
connective tissue and smooth muscle cells [3, 4],
(b) altered function of the venous endothelium [5],
(c) venous valve damage [6, 7],
(d) alterationsinmicrocirculationandvenouswallnour-
ishment [8, 9].
1.1. Nitric Oxide (NO). Is an important cellular-signaling
molecule, a potent vasodilatator due to the smooth muscle
relaxation. It also inhibits platelet adherence and aggre-
gation, reduces adherence of leukocytes to the endothe-
lium [10]. Furthermore, NO has been shown to inhibit DNA2 International Journal of Vascular Medicine
synthesis and mitogenesis, and the proliferation of vascular
smooth muscle cells. These antiproliferative eﬀects are likely
to be mediated by cyclic GMP [11].
1.2. Nitric Oxide Synthases (NOS). from the biochemical
point of view, are a family of complex enzymes catalyzing
the oxidation of L-arginine to form NO and L-citrulline.
The three human NOS isoforms identiﬁed to date are:
eNOS (endothelial NOS),nNOS (neuronal NOS), and iNOS
(inducible NOS). Their genes are found on human chromo-
somes 7, 12, and 17, respectively, and so they were named for
the tissue in which they were ﬁrst cloned and characterized
[10]. vasculoprotective eﬀect of individual NOS isoforms
in human organism is not suﬃciently clariﬁed yet [12].
Endothelial NOS (eNOS) and neuronal NOS (nNOS) are
constitutively expressed, mainly in endothelial cells and
nitrergic nerves, respectively, synthesizing a small amount of
NO under basal conditions and on stimulation by various
agonists. By contrast, inducible NOS (iNOS) is expressed
when stimulated by inﬂammatory stimuli, synthesizing a
largeamountofNOin atransient manner. The knowledgeof
nitric oxide synthases (NOSs) is of extreme scientiﬁc impor-
tance, not only for understanding new pathophysiological
mechanisms but also as a target for therapeutic intervention.
1.3. Endothelial Constitutive Nitric Oxide Synthase (eNOS).
The role of NO in regulating vascular tone and mediating
platelet function is attributable to the ongoing activity
of eNOS. It is pharmacologically identical with previ-
ously isolated EDRF (endothelium-derived releasing factor),
exprimed by the intact endothelium [13]. Inactivation of
the eNOS pathway limits the contribution of NO to vessel
homeostasis and results in increased vascular tone and
platelet adhesion and aggregation. The activity of eNOS
is regulated by the intracellular free calcium concentration
and calcium- calmodulin complexes. Endothelial NOS is
a constitutively expressed protein predominantly associated
with the particulate subcellular fraction, suggesting that the
native enzyme is a membrane-bound protein. A detailed
analysis of the membrane association of eNOS showed that
this enzyme is localized to the Golgi apparatus as well as
to speciﬁc structures in the plasmalemmal membrane called
caveolae. The association of eNOS with a region of the
plasma membrane in which several key signal-transducing
complexes are concentrated (such as G-proteins) is likely to
haveprofoundrepercussions onenzymeactivity aswell ason
its accessibility to intracellular mechanisms of the pathway
release, including mechanisms independent of intracellular
calcium release [10].
1.4. Neuronal Constitutive Nitric Oxide Synthase (nNOS).
This isoform is present in central and peripheral neuronal
cells and certain epithelial cells. Its activity is also regu-
lated by Ca2+ and calmodulin. Its functions include long-
term regulation of synaptic transmission in the central
nervoussystem, centralregulationofbloodpressure, smooth
muscle relaxation, and vasodilation via peripheral nitrergic
nerves. It has also been implicated in neuronal death in
Table 1: Varicose vein group of samples.
Males Females Together
Number 55 1 0
Average age
( i nt h et i m eo fp i c k u p ,i ny e a r s )
29,8 32,8 31,3
Age range (years) 22–37 24–42 22–42
Median (in years) 30 30 30
Table 2: Control group of healthy (non-dilated) samples.
Males Females Together
Number 73 1 0
Average age in the time of
pickup (in years)
26,1 30,3 27,4
Age range (years) 19–40 20–39 19–40
Median (in years) 26 32 26,5
cerebrovascular stroke [10]. NO plays also an important
role in the pathophysiology of some neurodegenerative
diseases. The presence of NO and NOS should be proved
indirectlythroughthehistochemicpositivityofnicotinamide
dinucleotide phosphate diaphorase (NADPHd) [14]. It was
proposed that nerve stimulation directly activated the release
of NO from nitrergic nerves and, in fact, NO appears to be
the dominant neurotransmitter responsible for the nerve-
mediated,endothelium-independentvasodilation[13].Este-
ban et al. (1998) documented the nNOS presence in the
livers of cat and rat; deducing from this that nitrergic ﬁbres
should be involved in the blood ﬂow regulation and further
metabolic functions of this organ [15].
Abd-El-Aleem et al. (2000) reported increased levels of
eNOS and iNOS in the chronic venous ulcers compared
with normal skin [16]. Howlader and Smith (2002) found
an increased levels of total NO in the blood of patients
with severe forms of chronic venous disease (healed venous
ulcers and lipodermatosclerosis) [17]. Our study was aimed
to ﬁnd a linkage betweenthe NOSsand thevenousdilatation
of primary varicose veins. The changes in NOSs isoforms
expression should help to elucidate the cause of the vessel
wall structural changes of the primary varicosis.
2.Materialand Methods
10 varicose vein samples of great saphenous veins [18]( 5
males and 5 females, see Table 1 for the age structure
of varicose vein group of samples) taken by the stripping
surgery in years 1997–2005 were compared with 10 control
samples of the lower limb superﬁcial veins (7 males and
3 females, see Table 2 for the age structure of the control
group of samples) taken from the necroptic material of
the Institute of Forensic Medicine (faculty of medicine,
Comenius University) in years 1999–2004 with no previous
history of any venous disease and no histological signs of
venous wall alterations, usually described by varicose vein
wall (phlebosclerosis, intimal thickening, ﬁbrosis of tunica
media, smooth muscle reduction, and clot formation). TheInternational Journal of Vascular Medicine 3
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Figure 1: The graph of the morphometric analysis results of the
expression of eNOS in varicose and control groups of samples (P<
.0001).
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Figure2:Thegraphofmorphometricanalysisresultsoftheexpres-
sionofnNOSinvaricoseandcontrolgroupsofsamples(P<. 0001).
Figure 3: Expression of eNOS in the tunica media of control
(healthy) vein (magniﬁcation400x, DAB).
Figure 4: Expression of eNOS in the tunica media of varicose vein
(magniﬁcation 400x, DAB).
Figure 5: Continuous eNOS cytoplasmatic expression in the
endothelial lining of the control (healthy) vein sample (magniﬁca-
tion 400x, DAB).
samples were immediately ﬁxed in the buﬀered formalin,
processed by the standard light microscopy method into
the paraﬃn blocks. The sections were then processed
by the standard immunohistochemic technique using the
rabbit polyclonal antibodies against both constitutive NOS
isoforms (eNOS from SantaCruz, USA and nNOS from
BioScience, USA). The expression of the antibodies was
evaluated semiquantitatively and also proved morphomet-
ricaly. By the semi quantitative evaluation, we concentrated
on the histologic characteristics of each section and the
localizationandintensityofmarker positivityintheveinwall
layers(− negative, +/− irregular positivity, + weak positivity,
++ medium positivity, +++ strong positivity). The semi
quantitative analysis was proved morphometricaly by the 2D
image analysis (ImageJ 1.34n, National Institute of Health,
USA).Thetotalarea ofNOSconstitutiveisoformexpressions
in tunica media was then determined by the color analysis
(the brown colorof NOS expression) and by the colordigital
subtraction was determined its portion of the total area of
tunica media. For the statistical analysis was used unpaired
t-test.4 International Journal of Vascular Medicine
Figure 6: Discontinuous, weak eNOS cytoplasmatic expression in
the endothelial lining of the varicose vein sample (magniﬁcation
630x, DAB).
Figure 7: Expression of nNOS in the tunica media of control
(healthy) vein sample (magniﬁcation 400x, DAB).
3.Results
The histomorphological and semi quantitative evaluation
of eNOS and nNOS isoforms showed discontinuous and
signiﬁcantly lower expression of both followed constitutive
NOS isoforms in the tunica media of the varicose veins
compared with control group, where the expression of both
NOS isoforms was continuous (see Figures 1 and 2).
For the Endothelial Isoform of NOS (eNOS). We found
continuous and diﬀuse expression of the followed marker
in tunica intima and media of the control samples, whereas
in the varicose samples, its expression was discontinuous.
Enhanced eNOS positivity was observed especially in the
endothelial lining of the vessels; in the healthy control
samples its expression was continuous over the whole
endothelial lining, and in the majority of the varicose
samplesitspositivityshowed discontinuityandinterruptions
in its expression (Figures 3, 4, 5,a n d6).
For the Neuronal NOS Isoform (nNOS). The histomorpho-
logical and semi quantitative evaluation showed lower and
Figure 8: Expression of nNOS in the tunica media of varicose vein
sample (magniﬁcation400x, DAB).
Figure 9: Enhanced nNOS positivity in the tunica intima (com-
pared with tunica media) of varicose vein of 30-yrear-old man
(V54), magniﬁcation 400x, DAB.
Figure 10: Enhanced nNOS positivity in tunica intima (compared
with tunica media) of varicose vein of 32-yrear-old man (V55),
magniﬁcation 200x, DAB.International Journal of Vascular Medicine 5
discontinuous expression of nNOS in tunica intima and
tunicamediaofthevaricoseveinsamplesincomparisonwith
the control samples (Figures 7 and 8). The only exceptions
were two varicose samples (V54, V55); in these varicose
samples the nNOS expression was higher in tunica intima
than in tunica media (Figures 9 and 10). Both samples
represent the varicose great saphenous vein samples of
relatively young men (30 and 32 years, resp.), taken by the
stripping surgery in the years of 2004 and 2005.
4.Discussion
Abd-El-Aleem et al. found increased levels of total NOS,
eNOS, iNOS, and arginase in the skin of chronic venous
ulcer by using immunocytochemistry, western blotting, and
enzyme assays [16]. Howlader and Smith (2002) observed
by the colorimetric method raised levels of total NO in the
blood plasma of the patients with severe chronic venous
disease—healed venous ulceration and lipodermatoclerosiss
(corresponding to C4 and C5 of CEAP classiﬁcation). In the
lesssevereCEAPstagesofthechronicvenousdisease(C2and
C3) the diﬀerence of total NO levels between diseased and
control subject was not statistically signiﬁcant [17].
I no u rs t u d y ,t h es t a g eo fC E A Po ft h ev a r i c o s e( d i l a t e d )
venous samples was not associated (not marked). So retro-
spectively, deducing from the fact that these varicose great
saphenousveinswere decidedforextraction (performing the
stripping surgery); these venous samples belonged to C2–C6
stages (according to CEAP classiﬁcation.)
For the endothelial NOS (eNOS),w ec o n ﬁ r m e dt h e
enhanced eNOS expression in the endothelial lining in
both followed groups: in the healthy (control) samples, the
eNOS expression was diﬀuse and continuous; whereas in
thevaricose samples the eNOSexpression was discontinuous
(Figures 5 and 6). This fact conﬁrms that eNOS is expressed
by the intact endothel, and that varicose veins are character-
ized by impaired endothelial function.
The expression of nNOS was also signiﬁcantly lower and
discontinuous in varicose compared with control (healthy)
vein samples; deducing that varicose dilatation is due to
other mechanisms than potentiated by peripheral nitrergic
ﬁbres in the varicose vein wall. The enhanced positivity
of nNOS in the tunica intima of two varicose samples
(V54 and V55, Figures 9 and 10) is probably due to other
unrecognized coincidental disease; by other varicose samples
the expression of these two markers in tunica intima copied
itsexpressionintunicamedia.Aswasmentionedabove,both
samples were varicose great saphenous veins of 30 and 32-
years-old males (respectively), and there was no diﬀerence
between the ﬁxation and processing of these two samples
compared with the rest of group.
Our summarized results are contradicting the results
of the two above-mentioned studies [16, 17], using two
other diﬀerent methods for the total NOS and eNOS
evaluation, which should perhaps be also due to supposed
earlier CEAP stages of venous samples in our study (not
associated). Nevertheless, our results should be conﬁrmed
by the measurement on more numerous sample groups with
marked associated CEAP stage of venous disease. From our
ﬁndings, we can now suppose that enhanced NO is not
responsible for varicose dilatation (especially in the earlier
CEAP stages), and so the venous wall weakness (the most
probable reason of primary varicosis) is a consequence of
some other pathophysiological mechanism.
5.Conclusion
Our results of signiﬁcantly lowered expressions of both
constitutive NOS isoforms suppose the lower nitric oxide
(NO) levels in varicose vein wall, deducing that the varicose
dilatation is due to other mechanism, although the stage
of chronic venous disease of the varicose vein samples was
undetermined (retrospectively deducing to the C2–C6stages
of CEAP); but we conﬁrmed the impaired function of the
varicose vein endothelium. These results shall also suggest
that NO level in varicose vein wall should undergo changes
depending on the stage of severity of chronic venous disease.
Several possibilities exist for proving the results of our
w o r k ,w es u g g e s tt or e p e a tt h em e t h o do nm o r en u m e r o u s
groups of samples (with marked CEAP stage of chronic
venous disease) to compare Ca2+ presence in vein walls and
to check the NOS and NO presence by the indirect histo-
chemic evidence of NADPHd positivity; the comparisons
of iNOS expression and the expressions of selected inﬂam-
matory stimuli are known for their potentiation of iNOS
expression (IL- 1β,I L - 6 ,T N F - α, etc.) As all NOS isoforms
utilize L-arginine as the substrate, with molecular oxygen
being the co-substrate [11], L-arginine inhibitors together
with ischemia should be considered in the prevention of
venousdilatationin case that resultsofourpreliminary work
fail to be conﬁrmed by further studies.
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